Samphire Neuroscience Ltd.

Samphire Neuroscience Ltd. is a London-based neurotechnology company founded in 2022 that develops brain-based medical devices for conditions linked to hormonal change in women. Its core thesis, stated on its own website, is that hormonal fluctuations do not merely affect mood but reshape neural circuitry, and that treatment should therefore begin with the brain rather than only with hormones. The company builds what it describes as advanced, brain-based technologies intended to give women a life free of pain and in control of their minds. Samphire's flagship product is the Samphire Headband, marketed under the name Nettle™. It is described as a medical-grade wearable therapeutic that manages both mood and pain symptoms linked to hormonal change via neuroplasticity. According to the company, the device has completed 50,000 sessions, 1,000,000 minutes of stimulation, and has been evaluated in 9 clinical trials, with 2 approved indications. A typical session involves 20 minutes of stimulation, with users completing roughly 7–10 sessions per month. Samphire states that 87.4% of existing users describe the product as "lifechanging." The treatment platform is powered by CycleSync™, a patented technology that maps cycle phases, conditions and symptom history to build a personalized treatment protocol. The protocol is adaptive, responding to short- and long-term cycle and hormonal changes. Samphire positions the headband as the only clinical-grade, approved treatment for managing chronic pain and mood symptoms associated with hormonal change. Samphire's stated clinical targets include PMDD (premenstrual dysphoric disorder), dysmenorrhea, perimenopause, chronic migraines and endometriosis. The company reports that a double-blind, randomised controlled trial demonstrated the headband outperformed placebo and existing options for premenstrual mood and period pain. The device received Class IIa medical device clearance in the United Kingdom and the European Union, and became available to users across those markets. Samphire has also completed PMDD clinical trials. The company was certified under ISO13485 as a manufacturer of quality medical devices. Samphire sells directly to users, with a guided-care model that includes an eligibility assessment before purchase. The company's website indicates shipping to the United States, with availability confirmed after an eligibility check. Samphire's CEO is Emilė Radytė, PhD, who introduces the company's platform publicly. The company is privately held and headquartered in London.

Samphire Neuroscience Ltd. was founded in 2022 in London, United Kingdom, with the goal of developing treatments that improve the lives of those living with chronic pain and mood conditions. From the outset, the company identified PMDD, dysmenorrhea, perimenopause, chronic migraines and endometriosis as its target conditions. The company's founding thesis is that hormonal fluctuations reshape neural circuitry, and that treatment should therefore begin with the brain. Samphire describes itself as building brain-based, advanced technologies that provide women with a life free of pain and in control of their minds. Early development focused on hardware. Samphire built the first version of the Samphire Headband, marketed as Nettle™. Hundreds of women were involved in usability testing of early versions, with the purpose of developing a safe, effective, easy-to-use, aesthetic and comfortable medical device. The company was subsequently certified under ISO13485 as a manufacturer of quality medical devices. Samphire then moved into clinical validation. A double-blind, randomised controlled trial demonstrated that the Samphire Headband outperformed placebo and existing options for premenstrual mood and period pain (dysmenorrhea). The company also completed clinical trials demonstrating efficacy in PMDD. In total, the company reports 9 clinical trials and 2 approved indications for the device. Regulatory progress followed. The Samphire Headband, under the name Nettle™, was granted Class IIa medical device clearance in the United Kingdom and the European Union. Market access then opened, and the headband became available to users across the United Kingdom and European Union. A limited number of Samphire Headbands were released directly to users and sold out; the company reports that over 87% of people who used the headband said it "transformed [their] lives." Samphire's platform is powered by CycleSync™, a patented technology that maps cycle phases, conditions and symptom history to build a tailored treatment protocol. The protocol is adaptive, responding to both short- and long-term cycle and hormonal changes. The company reports cumulative usage of 50,000 sessions and 1,000,000 minutes of stimulation, with a typical user completing 20 minutes of stimulation per session and 7–10 sessions per month. Samphire states that 87.4% of existing users describe Samphire as "lifechanging." Samphire sells directly to users through a guided-care model that includes an eligibility assessment. The company's website indicates shipping to the United States, with availability confirmed once eligibility is established. Samphire is headquartered in London and is privately held. Its CEO is Emilė Radytė, PhD.

• 2022

  Samphire Neuroscience Ltd. founded in London; target conditions identified (PMDD, dysmenorrhea, perimenopause, chronic migraines, endometriosis).

• First version of the Samphire Headband (Nettle™) built.

• Hundreds of women involved in usability testing of early headband versions.

• Samphire certified under ISO13485 as a manufacturer of quality medical devices.

• Double-blind, randomised controlled trial showed the Samphire Headband outperformed placebo and existing options for premenstrual mood and period pain.

• Samphire Headband (Nettle™) granted Class IIa medical device clearance in the United Kingdom and European Union.

• Samphire Headband became available to users across the United Kingdom and European Union.

• Limited release of Samphire Headbands directly to users sold out; over 87% of users said it "transformed [their] lives."

• Samphire completed clinical trials demonstrating efficacy in PMDD.

Medical-grade, brain-based wearable therapeutics for hormonal-change-related mood and pain conditions, sold direct to users with guided care.

• Nettle™ Samphire Headband

  A medical-grade wearable therapeutic proven to manage both mood and pain symptoms linked to hormonal change via neuroplasticity. 20 minutes of stimulation per session; 7–10 sessions per month typical. 50,000 sessions completed; 1,000,000 minutes of stimulation; 9 clinical trials; 2 approved indications.

• CycleSync™

  Patented technology that maps cycle phases, conditions and symptom history to build a tailored, adaptive treatment protocol.

1. 1Samphire Neuroscience | Unlocking the neuroscience of hormonal changesamphireneuro.com
2. 2About | Samphire Neurosciencesamphireneuro.com
3. 3Samphire Neuroscience Ltd. (United Kingdom) - Wikidatawikidata.org